Drug profile · INN
clopidogrel bisulfate
CLOPIDOGREL BISULFATE
clopidogrel bisulfate (CLOPIDOGREL BISULFATE) is a purinergic receptor p2y12 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — clopidogrel bisulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
clopidogrel bisulfate (CLOPIDOGREL BISULFATE) is a purinergic receptor p2y12 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Purinergic receptor P2Y12 antagonist
Primary target: P2Y purinoceptor 12
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is clopidogrel bisulfate?
clopidogrel bisulfate (CLOPIDOGREL BISULFATE) is a purinergic receptor p2y12 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clopidogrel bisulfate?
CLOPIDOGREL BISULFATE is a marketed brand name for clopidogrel bisulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clopidogrel bisulfate?
clopidogrel bisulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.